Steven Yu-Tsung Pei

Director Steven Yu-Tsung Pei purchases 250,000 shares at $4.09–$4.10 across 2 transactions ($1.0M), amid cluster buy and steep revenue decline.

Director Steven Yu-Tsung Pei executed 2 separate purchases totaling 250,000 shares for $1,024,225.00 at a blended average price of $4.10, raising his holdings from 1,618,323 to 1,868,323 shares. The stock currently trades at $4.08, near the transaction prices, and is down 15.0% from its 52-week high of $4.80 but has gained 16.9% over the past 30 days and 30.8% over 90 days. This purchase occurs alongside a cluster of 3 other insider buys within the past 14 days, suggesting coordinated accumulation at this price level. The company faces significant operational headwinds: annual revenue has contracted 48.5% year-over-year, and the most recent quarter showed revenue of $313,456.00 with a net loss of $9,383,417.00, indicating the company is unprofitable on both quarterly and full-year basis. The timing of this director-level accumulation during a period of severe revenue deterioration and a recent near-52-week-high price level presents a mixed signal warranting examination of management's stated rationale for the purchases.

Director Steven Yu-Tsung Pei purchased 360,000 shares across 3 transactions (Jun 1-3, 2026) at blended $4.02; largest buy in LODE holdings (+23.5%)

Director Steven Yu-Tsung Pei executed 3 separate purchases totaling 360,000 shares for $1,446,677.49 over three consecutive trading days, raising his holdings from 1,530,980 shares to 1,890,980 shares—a 23.5% increase in his position at the company. The purchases occurred at prices ($4.14, $4.10, and $3.93) clustering near recent trading levels, with the blended average of $4.02 just above the current price of $3.92, placing the transaction in the 52-week context of -18.3% from the high but +21.4% over the prior 30 days. Notably, his prior two purchases at LODE (May 13 and May 14) both demonstrated positive 90-day returns of 23.0% and 21.2% respectively, establishing a pattern of well-timed entries at this ticker. However, the company's fundamentals present a contrasting backdrop: latest quarterly revenue was $313,456.00, net income stands at $-9,383,417.00, annual revenue growth is -48.5%, and the company remains unprofitable on a full-year basis, suggesting the director's accumulation may reflect conviction at depressed valuations or a structural belief disconnected from near-term earnings recovery.

Director Pei Steven Yu-Tsung bought 424,559 shares (424.6K) for $1,436,864.58 at blended $3.38; post-transaction holding 1,530,980 shares (1.53M).

Director Pei Steven Yu-Tsung executed a substantial two-day purchase of 424,559 shares (424.6K shares) for $1,436,864.58, increasing his stake from 7,993 shares to 1,530,980 shares (1.53M shares)—a net acquisition of 1,522,987 shares that represents a dramatic expansion of his position in the company. The purchases occurred at $3.38 and $3.42, prices that sit near the current market price of $3.32 and within the 52-week range of $2.24–$4.80, though notably -30.8% below the 52-week high, suggesting acquisition during a relative pullback. However, the company's operational context presents significant headwinds: latest-quarter revenue is only $313,456.00 ($313.5K) with a net loss of $-9,383,417.00 ($-9.4M), while annual revenue declined -48.5% year-over-year and the firm remains unprofitable with a market cap of $252,031,438.88 ($252.0M). This large insider purchase by a director conflicts with the company's deteriorating financial position, warranting scrutiny into whether the acquisition reflects conviction in a turnaround narrative or reflects other considerations such as internal information asymmetry.